Published in J Infect Dis on August 01, 2011
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB | NCT02660346
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis (2013) 2.44
Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev (2012) 2.18
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis (2016) 2.08
Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis (2012) 1.70
Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis (2011) 1.41
Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 1.38
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc (2011) 1.33
A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev (2013) 1.24
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother (2014) 1.17
High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis (2012) 1.11
Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep (2012) 1.08
Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol (2012) 1.07
Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol (2013) 0.99
Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist (2012) 0.88
Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis (2014) 0.86
Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2012) 0.86
Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression. Antimicrob Agents Chemother (2012) 0.86
Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates. J Clin Microbiol (2014) 0.84
Vancomycin minimum inhibitory concentrations and lethality in Staphylococcus aureus bacteremia. Germs (2015) 0.83
Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry. Adv Ther (2015) 0.82
Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome. Pediatr Infect Dis J (2016) 0.82
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother (2015) 0.82
Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr (2014) 0.81
Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother (2016) 0.80
Reduced susceptibility to vancomycin in Staphylococcus aureus. Emerg Infect Dis (2011) 0.80
Biotin Protein Ligase Is a Target for New Antibacterials. Antibiotics (Basel) (2016) 0.79
Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant Staphylococcus aureus strain USA600 (ST45) are associated with increased mortality in a hospital setting. J Clin Microbiol (2014) 0.79
Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis (2016) 0.77
Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials. Clin Infect Dis (2012) 0.77
Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in Staphylococcus aureus bacteraemia. Epidemiol Infect (2012) 0.77
High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus. Emerg Infect Dis (2016) 0.76
Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patients. J Clin Microbiol (2013) 0.76
Comparison of Outcomes among Adult Patients with Nosocomial Bacteremia Caused by Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus: A Retrospective Cohort Study. PLoS One (2015) 0.76
Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 0.76
Impact of Vancomycin Minimum Inhibitory Concentration on Treatment Outcomes in Invasive Staphylococcus aureus Infections. Antimicrob Agents Chemother (2016) 0.75
Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children. J Korean Med Sci (2017) 0.75
Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia. Clin Infect Dis (2017) 0.75
Discordant minimum inhibitory concentration analysis: a new path to licensure for anti-infective drugs. Clin Trials (2013) 0.75
Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application. Drugs Aging (2016) 0.75
Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia. J Pediatr Pharmacol Ther (2017) 0.75
Fatal endocarditis with methicilin-sensible Staphylococcus aureus and major complications: rhabdomyolysis, pericarditis, and intracerebral hematoma: A case report and review of the literature. Medicine (Baltimore) (2016) 0.75
Differences in Method-Specific Vancomycin MICs and Induced Daptomycin Resistance in an Infective Endocarditis Patient. Case Rep Infect Dis (2015) 0.75
Early high-dose daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentrations: ready for prime time? Clin Infect Dis (2013) 0.75
Vancomycin minimum inhibitory concentrations and outcome in patients with severe Staphylococcus aureus infection. J Infect Dis (2012) 0.75
Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World J Crit Care Med (2016) 0.75
Identification of Low-Level Vancomycin Resistance in Staphylococcus aureus in the Era of Informatics. J Clin Microbiol (2016) 0.75
Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration. PLoS One (2015) 0.75
CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials (2016) 0.75
Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrob Agents Chemother (2017) 0.75
Role of high vancomycin minimum inhibitory concentration in the outcome of methicillin-susceptible Staphylococcus aureus bacteremia. J Infect Dis (2012) 0.75
Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection. Antimicrob Agents Chemother (2017) 0.75
Relationship between pathogenic, clinical, and virulence factors of Staphylococcus aureus in infective endocarditis versus uncomplicated bacteremia: a case-control study. Eur J Clin Microbiol Infect Dis (2016) 0.75
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol (2002) 10.88
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
An analysis of human microRNA and disease associations. PLoS One (2008) 5.21
Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services. Med J Aust (2013) 4.93
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents (2005) 4.71
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res (2007) 3.45
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res (2008) 3.26
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis (2010) 2.98
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem (2006) 2.95
Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect (2008) 2.88
Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples. Appl Environ Microbiol (2007) 2.75
Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis (2004) 2.66
2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis (2010) 2.60
SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis (2008) 2.56
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 2.43
Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother (2003) 2.42
The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis (2008) 2.39
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother (2004) 2.36
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem (2006) 2.35
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother (2003) 2.30
Hair cortisol as a biomarker of traumatization in healthy individuals and posttraumatic stress disorder patients. Biol Psychiatry (2013) 2.30
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust (2009) 2.16
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol (2014) 2.12
Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc (2005) 2.12
Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis (2012) 2.08
Methicillin-resistant Staphylococcus aureus in hospitals: time for a culture change. Med J Aust (2007) 2.06
Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis (2005) 2.04
Conundrums in community-acquired pneumonia. Med J Aust (2006) 2.04
What's hanging around your neck? Pathogenic bacteria on identity badges and lanyards. Med J Aust (2008) 2.03
Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother (2002) 2.02
Amino acid conjugated sophorolipids: A new family of biologically active functionalized glycolipids. Bioconjug Chem (2006) 2.01
Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis (2011) 2.00
An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis (2012) 1.97
Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol (2006) 1.91
Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.89
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother (2009) 1.83
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis (2002) 1.83
Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med (2014) 1.80
A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis (2010) 1.80
Graphene quantum dots derived from carbon fibers. Nano Lett (2012) 1.79
Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis (2012) 1.78
Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis (2013) 1.76
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother (2008) 1.75
Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog (2010) 1.74
Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother (2008) 1.74
Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust (2006) 1.73
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Outbreak investigation using high-throughput genome sequencing within a diagnostic microbiology laboratory. J Clin Microbiol (2013) 1.71
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis (2010) 1.70
Emergence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection in Queensland, Australia. Int J Infect Dis (2003) 1.68
Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol (2002) 1.68
Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis (2009) 1.67
In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.66
Ceftriaxone and cefotaxime use in Victorian hospitals. Med J Aust (2002) 1.63
Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust (2011) 1.62
Nano/Microscale motors: biomedical opportunities and challenges. ACS Nano (2012) 1.61
A new linearized Crank-Nicolson mixed element scheme for the extended Fisher-Kolmogorov equation. ScientificWorldJournal (2013) 1.58
Does linezolid modulate lung innate immunity in a murine model of methicillin-resistant Staphylococcus aureus pneumonia? Crit Care Med (2011) 1.57
The effect of obesity on outcomes in trauma patients: a meta-analysis. Injury (2012) 1.56
First case of Mycobacterium ulcerans disease (Bairnsdale or Buruli ulcer) acquired in New South Wales. Med J Aust (2007) 1.56
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust (2007) 1.56
Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun (2002) 1.54
Rapid detection of vanA and vanB genes directly from clinical specimens and enrichment broths by real-time multiplex PCR assay. J Clin Microbiol (2003) 1.53
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob Agents Chemother (2002) 1.52
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). Antimicrob Agents Chemother (2008) 1.50
Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem (2006) 1.49
Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene. Antimicrob Agents Chemother (2007) 1.46
Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol (2008) 1.46
Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother (2008) 1.46
Retracted Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis. Eur J Med Res (2014) 1.45
Duration of in vivo antimicrobial activity of antibiotic-impregnated cerebrospinal fluid catheters. Neurosurgery (2006) 1.45
Non-multiresistant methicillin-resistant Staphylococcus aureus bacteraemia in Sydney, Australia: emergence of EMRSA-15, Oceania, Queensland and Western Australian MRSA strains. Pathology (2006) 1.44
Overexpression of Arabidopsis acyl-CoA binding protein ACBP3 promotes starvation-induced and age-dependent leaf senescence. Plant Cell (2010) 1.43
Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother (2006) 1.43
Complete genome sequence of Staphylococcus aureus strain JKD6008, an ST239 clone of methicillin-resistant Staphylococcus aureus with intermediate-level vancomycin resistance. J Bacteriol (2010) 1.43